rmdopen.bmj5d
Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases
Background Patients with immune-mediated rheumatic diseases (IMRDs) are commonly treated with immunosuppressors and prone to infections. Recently introduced mRNA SARS-CoV-2 vaccines have demonstrated ...
rmdopen.bmj3d
Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis
Objectives To compare outcomes of targeted treatment aimed at either low disease activity or remission in patients with early active rheumatoid arthritis (RA). Methods Five-year outcomes were compared ...
rmdopen.bmj5d
Humoral and cellular SARS-CoV-2 vaccine responses in patients with giant cell arteritis and polymyalgia rheumatica
Objectives Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are overlapping autoinflammatory diseases affecting people over 50 years. The diseases are treated with immunosuppressive drugs ...
rmdopen.bmj7d
Low prevalence of anti-SSA (anti-Ro) and anti-SSB (anti-La) autoantibodies in female patients with rheumatoid arthritis with a wish to conceive
Objectives Guidelines advise to test for anti–Sjögren's-syndrome-related antigen A (anti-SSA) and anti–Sjögren's-syndrome-related antigen B (anti-SSB) antibodies in all patients with rheumatoid ...
rmdopen.bmj12d
Patient appropriateness for total knee arthroplasty and predicted probability of a good outcome
Objectives One-fifth of total knee arthroplasty (TKA) recipients experience a suboptimal outcome. Incorporation of patients’ preferences in TKA assessment may improve outcomes. We determined the ...
rmdopen.bmj7d
Suitability for e-health of non-pharmacological interventions in connective tissue diseases: scoping review with a descriptive analysis
Objective Non-pharmacological interventions support patients with connective tissue diseases to better cope with and self-manage their diseases. This study aimed to map existing evidence on ...
rmdopen.bmj6d
Anticoagulation in venous thromboembolism in Behçet’s syndrome: friend or foe?
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
rmdopen.bmj29d
Anatomical pattern of entheseal and synovial fibroblast activation in patients with psoriasis and its risk of developing psoriatic arthritis
Correspondence to Dr Filippo Fagni; Filippo.Fagni{at}uk-erlangen.de Conclusions Patients with psoriasis presenting with arthralgia show localised signs of resident tissue activation in joints and ...
rmdopen.bmj16d
Pneumococcal vaccination in autoimmune rheumatic diseases
1 Institute of Infectious Diseases, University of Debrecen Faculty of Medicine, Kenézy University Hospital, Debrecen, Hungary Streptococcus pneumoniae is the leading cause of the community-acquired ...
rmdopen.bmj26d
Lymphoma complicating rheumatoid arthritis: results from a French case–control study
Objectives To study the characteristics of B-cell non-Hodgkin’s lymphoma (NHL) or Hodgkin lymphoma complicating rheumatoid arthritis (RA) and to identify RA-related factors associated with their ...
rmdopen.bmj23d
Impact of filgotinib on pain control in the phase 3 FINCH studies
Present affiliation The present affiliation of Shangbang Rao is: Candel Therapeutics, Needham, MA, USA Present affiliation The present affiliation of Pieter-Jan Stiers is: AgomAb Therapeutics, Ghent, ...
rmdopen.bmj28d
Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial
Objectives The objectives of this study are to identify a therapeutic serum level for adalimumab associated with remission and low disease activity in patients with rheumatoid arthritis. Methods ...